Table 1. Baseline demographic and clinical characteristics by intervention groups.
| All | Intervention groups |
||||
|---|---|---|---|---|---|
| 3 × 105 pfu | 1 × 107 pfu* | 5 × 107 pfu* | Placebo† | ||
| Group size, n | 115 | 51 | 35 | 16 | 13 |
| Baseline demographics | |||||
| Age, years | 41 (12) | 40 (12) | 42 (11) | 43 (14) | 41 (12) |
| Sex | |||||
| Female | 53 (46%) | 27 (53%) | 14 (40%) | 5 (31%) | 7 (54%) |
| Male | 62 (54%) | 24 (47%) | 21 (60%) | 11 (69%) | 6 (46%) |
| Ethnic origin | |||||
| White | 108 (94%) | 51 (100%) | 29 (83%) | 15 (94%) | 13 (100%) |
| Other | 7 (6%) | 0 | 6 (17%) | 1 (6%) | 0 |
| Deployability | |||||
| Deployable | 38 (33%) | 13 (26%) | 18 (51%) | 7 (44%) | 0 |
| Non-deployable | 77 (67%) | 38 (75%) | 17 (49%) | 9 (56%) | 13 (100%) |
| Clinical characteristics | |||||
| Haemoglobin, g/L | 143·1 (13·1) | 143·0 (13·7) | 143·1 (14·1) | 144·3 (11·2) | 142·1 (10·7) |
| Platelets, g/L | 244·7 (54·6) | 249·7 (60·7) | 246 (47·6) | 234·6 (45·3) | 234·4 (60·5) |
| Leucocytes, g/L | 6·21 (1·8) | 6·44 (2·1) | 5·9 (1·2) | 6·6 (2·1) | 5·7 (1·4) |
| Lymphocytes, g/L | 2·0 (0·5) | 2·0 (0·6) | 2·0 (0·5) | 2·0 (0·5) | 2·0 (0·7) |
| Neutrophils, g/L | 3·5 (1·5) | 3·7 (1·7) | 3·3 (1·0) | 3·8 (1·8) | 3·0 (1·0) |
| Monocytes, g/L | 0·5 (0·2) | 0·5 (0·2) | 0·5 (0·2) | 0·6 (0·2) | 0·5 (0·1) |
| Creatinine, mg/dL | 76·2 (12·3) | 73·7 (11·9) | 78·2 (11·2) | 81·7 (13·8) | 73·6 (12·9) |
| AST, U/L | 15·3 (5·5)‡ | 15·0 (5·5)‡ | 15·3 (5·3) | 15·4 (6·5) | 16·1 (5·6) |
| ALT, U/L | 18·9 (11·1) | 18·3 (8·3) | 21·1 (14·8) | 15·5 (6·3) | 19·8 (13·0) |
Data are n (%) or mean (SD). pfu=plaque-forming units. AST=aspartate aminotransferase. ALT=alanine aminotransferase.
*
As previously described.9
†
Placebo recipients from both dose groups did not differ significantly (appendix p 13) and were pooled.
‡
Data missing for one participant.